



Georgia Department of Public Health: Strike & Support Team GADPH Office Hours for NHs & SNFs June 16, 2023



Meet the Team



Presenters:

Swati Gaur, MD, MBA, CMD, AGSFMedical Director, Alliant Health Solutions

Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist Alliant Health Solutions



Swati Gaur, MD, MBA, CMD, AGSF

MEDICAL DIRECTOR, POST-ACUTE CARE NORTHEAST GEORGIA HEALTH SYSTEM

Dr. Swati Gaur is the medical director of New Horizons Nursing Facilities with the Northeast Georgia Health System. She is also the CEO of Care Advances Through Technology, a technology innovation company. In addition, Dr. Gaur is on the electronic medical record (EMR) transition and implementation team for the health system, providing direction to EMR entity adaption to the long-term care (LTC) environment. She has also consulted with post-acute long-term care (PALTC) companies on optimizing medical services in PALTC facilities, integrating medical directors and clinicians into the QAPI framework, and creating frameworks of interdisciplinary work in the organization. Dr. Gaur established the palliative care service line at the Northeast Georgia Health System.

She also is an attending physician in several nursing facilities. Dr. Gaur attended medical school in Bhopal, India, and started her residency in internal medicine at St. Luke's–Roosevelt Medical Center in New York. She completed her fellowship in geriatrics at the University of Pittsburgh Medical Center and is board certified in internal medicine, geriatrics, hospice, and palliative medicine. In addition, she earned a master's in business administration at the Georgia Institute of Technology with a concentration in technology management.





Erica Umeakunne, MSN, MPH, APRN, CIC

Infection Prevention Specialist Alliant Health Solutions

Erica Umeakunne is an adult-gerontology nurse practitioner and infection preventionist with experience in primary care, critical care, health care administration and public health.

She was previously the interim hospital epidemiology director for a large health care system in Atlanta and a nurse consultant in the Center for Disease Control and Prevention's (CDC) Division of Healthcare Quality Promotion. While at the CDC, she served as an infection prevention and control (IPC) subject matter expert for domestic and international IPC initiatives and emergency responses, including Ebola outbreaks and, most recently, the COVID-19 pandemic.



Erica enjoys reading, traveling, family time, and outdoor activities.

Contact: <u>Erica.Umeakunne@allianthealth.org</u>



Thank You to Our Partners

- Georgia Department of Public Health
- University of Georgia








Objectives

- Provide updates on the COVID-19 epidemiology and the COVID-19 vaccination program
- Examine the updated infection prevention and control (IPC) recommendations and provide situational examples
- Share Alliant Health Solutions resources to support COVID-19 IPC activities
- Address any facility-specific IPC questions or concerns







CDC Data and Surveillance: Available Metrics

()Eme	Emergency Department COVID-19 visits (weekly)		
	COVID-19 hospital admissions		
	COVID-19 deaths (data source change)		
$\mathbf{\Upsilon}$			
) Wastewater surveillance		
	Genomic surveillance		
	COVID-19 vaccine administration data (limited)		
\bigcirc CO	VID-19 test positivity (data source change)		




Transm: vels

- vention and actions
 - a he setting lows for tervention etter prote duals se
 - edical care


COVID-19 Community Levels Non health

- Non-heal' living facilities mes, recommendate semi
- Hel dommunitie le who ever ons to take it on the tinform.
- Intendividual-pre n behaviors proved strategies for high
 Intendividual-pehold-proved proved not strategies for high






CDC COVID-19 Data Tracker









Wastewater Surveillance

Metric:

- Current virus levels in wastewater by site
- O Percent change in the last 15 days
- O Percent of wastewater samples with detectable virus


Show:

- ✓ Sites with no recent data
- ✓ Sites that started sampling after 12/1/21

Current virus levels in wastewater by site

This metric shows whether SARS-CoV-2 levels at a site are currently higher or lower than past historical levels at the same site. 0% means levels are the lowest they have been at the site; 100% means levels are the highest they have been at the site. Public health officials watch for increasing levels of the virus in wastewater over time and use these data to help make public health decisions.

▲ Note: Sites began collecting data at different times. Sites that began reporting wastewater data after December 1, 2021 are not comparable to sites that started reporting data on or before December 1, 2021. The data history for these new sites is not long enough to reflect the same surges as the other sites.




Current SARS-CoV-2 virus levels by site, United States

Current virus levels category		Num. sites		Category change in last 7 days
	New Site	148	12	1%
	0% to 19%	529	41	- 2%
	20% to	429	34	- 12%




Wastewater Surveillance





Wastewater Surveillance



Percent change of SARS-CoV-2 in the last 15 days by site, United States

C	5-day % hange ategory	Num. sites		Category change in last 7 days
	- 100%	39	4	77%
	– 99% to – 10%	372	37	- 35%
	– 9% to 0%	62	6	- 48%
	1% to 9%	56	6	- 27%
	10% to 99%	178	18	- 21%
	100% to 999%	180	18	1%
	1000% or more	119	12	80%

Total sites with current data: 1006


Total number of wastewater sampling

sites: 1552

How is the 15-day percent change calculated?




Confirmed COVID-19 Cases among Residents and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States







Confirmed COVID-19 Cases among Staff and Rate per 1,000 Resident-Weeks in Nursing Homes, by Week—United States














COVID-19 hospital admissions levels in US by county Based on new COVID-19 hospital admissions per 100,000 population Total Percent % Change ≥ 20.0 5 0% 0.16% 10.0 - 19.9 26 0.81% 0.71% <10.0 3191 99.04% -0.74%

Time Period: New COVID-19 hospital admissions per 100,000 population (7-day total) are calculated using data from the MMWR week (Sun-Sat) ending June 3, 2023.


US Reported COVID-19 New Hospital Admissions Rate per 100,000 in the Past Week, by County




High => 20 new COVID-19 admissions per 100,000 population over the last 7 days

Universal source control











Resident Safety Against COVID-Related Serious Outcomes and Long COVID

Bivalent vaccine

Sustained increased protection against ICU admissions, death

Protection against Long COVID

Therapeutics

Oral therapeutics:

Paxlovid

- Protection against hospitalization and death
- ➤ Protection against Long COVID

Lagevrio

Ability to dissolve

Parenteral therapeutics:

Remdesivir

LIVES SAVED



Changes in Vaccine Recommendations





New recommendations for people aged ≥6 years without immunocompromise who have not yet received a bivalent mRNA dose

One bivalent mRNA dose




New recommendations for people aged ≥6 years without immunocompromise who have not yet received any COVID vaccine.

One bivalent mRNA dose




New recommendations for aged ≥6 years without immunocompromise who have already received a bivalent mRNA dose



Vaccination is complete. No doses are indicated at this time.



Flexible for people at higher risk of severe COVID-19: People aged ≥65 years who have already received a bivalent mRNA dose






COVID Vaccine Options

mRNA Vaccines - Pfizer/Moderna

ONE & DONE

Novavax – Manufactured like Influenza vaccine





Use of Timely Therapeutics in COVID-19

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop C2-21-16 Baltimore, Maryland 21244-1850



Center for Clinical Standards and Quality

Ref: QSO-23-03-All

DATE: November 22, 2022

TO: State Survey Agency Directors

FROM: Directors, Quality, Safety & Oversight Group (QSOG) and Survey &

Operations Group (SOG)

SUBJECT: The Importance of Timely Use of COVID-19 Therapeutics

Memorandum Summary

- Providers and suppliers, especially those delivering care in congregate care settings, should
 ensure their patients and residents are protected against transmission of COVID-19 within
 their facilities, as well as receiving appropriate treatment when tested positive for the virus.
- Further, all providers and suppliers should continue to implement appropriate infection control protocols for COVID-19 (https://www.cdc.gov/coronavirus/2019-ncov/hcp/infectioncontrol.html) and Influenza (https://www.cdc.gov/flu/professionals/infectioncontrol/index.htm).
- This memo discusses the importance of the timely use of available COVID-19 therapeutics, particularly for high-risk patients who test positive for the virus.

https://www.covid19treatmentguidelines.nih.gov/management/clinical-management-of-adults/nonhospitalized-adults--therapeutic-management/

Table 2a. Therapeutic Management of Nonhospitalized Adults With Mild to Moderate COVID-19 Who Do Not Require Supplemental Oxygen

Last Updated: April 20, 2023

Patient Disposition	Panel's Recommendations		
All Patients	 Symptom management should be initiated for all patients (AIII). The Panel recommends against the use of dexamethasone^a or other systemic corticosteroids in the absence of another indication (AIIb). 		
Patients Who Are at High Risk of Progressing to Severe COVID-19 ^b	Preferred therapies. Listed in order of preference: Ritonavir-boosted nirmatrelvir (Paxlovid) ^{c,d} (Alla) Remdesivir ^{d,e} (Blla)		
	Alternative therapy. For use when the preferred therapies are not available, feasible to use, or clinically appropriate: • Molnupiravir ^{d,f,g} (Clia)		



Flu Guidance Updated ACIP 2023

ADULTS AGED ≥65 YEARS


 ACIP recommends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (allV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other ageappropriate influenza vaccine should be used.



Flu Vaccines for > 65 Years

Quadrivalent IIV (HD-IIV4)—High-dose—Egg-based (60 μg HA per virus component in 0.7 mL)						
Fluzone High-Dose Quadrivalent Sanofi Pasteur	0.7 mL prefilled syringe	≥65 yrs	≥65 yrs—0.7 mL			
Adjuvanted quadrivalent IIV4 (a	Adjuvanted quadrivalent IIV4 (aIIV4)—Standard-dose with MF59 adjuvant—Egg-based (15 µg HA per virus component in 0.5 mL)					
Fluad Quadrivalent	0.5 mL prefilled syringe	≥65 yrs	≥65 yrs —0.5 mL			
Seqirus						
Quadrivalent RIV (RIV4)—Recombinant HA (45 μg HA per virus component in 0.5 mL)						
Flublok Quadrivalent Sanofi Pasteur	0.5 mL prefilled syringe	≥18 yrs	≥18 yrs—0.5 mL			









COVID-19 Infection Prevention and Control Guidance Updates

- Updates
 - Facility-wide use of source control (masking)
 - Admission testing in nursing homes
 - Interim Infection Prevention and Control Recommendations for Healthcare Personnel During the Coronavirus Disease 2019 (COVID-19) Pandemic
- No updates
 - Interim Guidance for Managing Healthcare Personnel with SARS-CoV-2 Infection or Exposure
 - Strategies to Mitigate Healthcare Personnel Staffing Shortages



COVID-19 IPC Guidance Updates: Source Control

- No longer guided by the Transmission Levels (previous metric)
- Source control broadly recommended as described in the <u>CDC's Core IPC Practices</u> in the following circumstances:
 - During SARS-CoV-2 outbreak or other respiratory infection outbreak
 - Facility-wide or, based on a facility risk assessment, targeted toward higher risk areas or patient or resident population
 - When recommended by public health authorities (e.g., in guidance for the community when COVID-19 hospital admission levels are high)



Broader Use of Source Control: Potential Metrics

- Consider masking during typical respiratory virus season (~October to April)
- COVID Hospital Admission levels
 - High => 20 new COVID-19 admissions per 100,000 population over the last 7 days
- Follow national (or local, if available) data on trends of several respiratory viruses
 - RESP-NET interactive dashboard
 - National Emergency Department Visits for COVID-19, Influenza, and Respiratory Syncytial Virus
 - ILINET



COVID-19 IPC Guidance Updates: Admission Testing in Nursing Homes

- At the discretion of the nursing home (similar to other health care settings)
 - Considerations for pre-admission or pre-procedure testing for asymptomatic individuals are detailed in the <u>Interim Infection</u> <u>Prevention and Control Recommendations for Healthcare</u> <u>Personnel During the Coronavirus Disease 2019 (COVID-19)</u> <u>Pandemic</u>



COVID-19 IPC Updates

Admission Screening

• Admission testing is at the discretion of the facility, no longer guided by the Transmission Levels (previous metric)

Source Control

- •No longer guided by the Transmission Levels (previous metric)
- Health care facilities should identify local metrics that could reflect increasing community respiratory viral activity to determine when broader use of source control in the facility might be warranted

Staff Screening

No change

•Screening testing of asymptomatic HCP is at the discretion of the health care facility.

Exposure/Close Contact

No change

• Asymptomatic patients/residents with close contact with someone with SARS-CoV-2 infection should have a series of three viral tests for SARS-CoV-2 infection.

Outbreak Investigations

No change

• A single new case of SARS-CoV-2 infection in any HCP or resident should be evaluated to determine if others in the facility could have been exposed.



Scenario 1: Admission Testing

Mr. Jones has been a resident at Sunshine Health Nursing Facility for the past year. Mr. Jones is a 72-year-old male with a history of heart failure, diabetes type II and renal failure. He receives hemodialysis 3x/week at the local dialysis clinic. During yesterday's dialysis session, he experienced abnormal heart rhythms accompanied by chest discomfort. His dialysis session was stopped, and he was subsequently transferred to the local hospital for evaluation and admitted for observation for 48 hours. He is now stable and ready to return to Sunshine Health Nursing Facility. Should the facility obtain a COVID-19 (admission) test upon Mr. Jones' arrival?

A. Yes

- B. No
- C. I'm not sure
- D. I need more information



Scenario 1: Admission Testing

Should the facility obtain a COVID-19 (admission) test upon Mr. Jones' arrival?

- A. Yes
- B. No
- C. I'm not sure
- D. I need more information

- Residents who leave the facility for 24 hours or longer should generally be managed as an admission
- ✓ In general, the performance of preprocedure or pre-admission testing is at the discretion of the facility.
- Considerations (more information)
 - ✓ Facility admission testing policy/procedure
 - ✓ Resident population risk
 - ✓ Known COVID-19 exposures while hospitalized
 - ✓ Weekly COVID-19 hospital admissions
 - ✓ Weekly COVID-19 percentage death
 - ✓ Emergency department visits



Although COVID-19 cases and associated hospitalizations have decreased in recent months, COVID-19 remains an ongoing public health challenge

Updated public health tracking* will keep you informed about COVID-19

Hospital admissions



Spread in communities + severity of illness

Death certificates



Severity of illness

Emergency department visits



track

Early signs of spread

Genomic sequencing





New variants



Check COVID.cdc.gov to know when to take action


"To account for changes in available data after the end of the U.S. Public Health Emergency declaration


bit.ly/mm7219e1

MAY 5, 2023









https://covid.cdc.gov/covid-data-tracker/#cases_new-admissions-rate-county

https://covid.cdc.gov/covid-datatracker/#trends_weeklyhospitaladmissions_weekl ypctdeaths_13



Scenario 2: Staff Screenings

Nurse Smith arrived this morning for her shift. She shares that she is returning from vacation. She states she feels fatigued but attributes it to traveling. She also mentions that she has a cough and runny nose, which she attributes to allergies. Her records indicate that she is up to date with her COVID-19 vaccinations. Should the administration conduct a COVID-19 test on Nurse Smith before she starts her shift?

- A. Yes
- B. No



Scenario 2: Staff Screenings

Nurse Smith arrived this morning for her shift. She shares that she is returning from vacation. She states she feels mildly fatigued but attributes it to traveling. She also mentions that she has a cough and runny nose, which she attributes to allergies. Her records indicate that she is up to date with her COVID-19 vaccinations. Should the administration conduct a COVID-19 test on Nurse Smith before she starts her shift?

- A. Yes
- B. No

- ✓ Exhibiting COVID-19 symptoms
- ✓ Anyone with even mild symptoms of COVID-19, regardless of vaccination status, should receive a viral test for SARS-CoV-2 as soon as possible.
- Health care personnel with even mild COVID-19 symptoms should be prioritized for viral testing with nucleic acid or antigen detection assays.
 - ✓ When testing a person with symptoms of COVID-19, negative results from at least one viral test indicate that the person most likely does not have an active SARS-CoV-2 infection when the sample was collected.



Scenario 3: Source Control

The administrator's or IP's immediate next step, in addition to COVID-19 testing, should be to ensure Nurse Smith is wearing source control.

- A. True
- B. False



Scenario 3: Source Control

The administrator's or IP's immediate next step, in addition to COVID-19 testing, should be to ensure Nurse Smith is wearing source control.

- A. True
- B. False

- ✓ Source control is recommended for individuals in health care settings who:
 - ✓ Have suspected or confirmed SARS-CoV-2 infection or other respiratory infection (e.g., those with runny nose, cough, sneeze); or
 - ✓ Had <u>close contact</u> (patients and visitors) or a <u>higher-risk</u> <u>exposure</u> (HCP) with someone with SARS-CoV-2 infection for 10 days after their exposure



Scenario 4: Outbreak Investigation

Today, a CNA reported a positive COVID-19 result from a viral SARS-CoV-2 PCR test taken two days ago. His last and only shift in the past week was on 6/12/2023 from 7 a.m. - 3 p.m., and he was sent home early for not feeling well (reporting a runny nose, sore throat, fatigue, and headache).

Does this constitute a COVID-19 outbreak and require an outbreak investigation?

A.Yes

B. No



Scenario 4: Outbreak Investigation


Today, a CNA reported a positive COVID-19 result from a viral SARS-CoV-2 PCR test taken two days ago. His last and only shift in the past week was on 6/12/2023 from 7 a.m. - 3 p.m., and he was sent home early for not feeling well (reporting a runny nose, sore throat, fatigue, and headache).

Does this constitute a COVID-19 outbreak and require an outbreak investigation?

- A. Yes
- B. No

- ✓ A single new case of SARS-CoV-2 infection in any HCP or resident should be evaluated to determine if others in the facility could have been exposed.
- ✓ Outbreak investigation approach
 - ✓ Contact tracing **OR** a broadbased approach
 - ✓ Perform testing for all residents and HCP identified as close contacts or on the affected unit(s) if using a broad-based approach, regardless of vaccination status







CMS Guidance Updates

This <u>rule</u> makes three key changes:

- Removes expired language addressing staff and resident COVID-19 testing requirements issued in the interim final rule (IFR) "LTC Facility Testing" on September 2, 2020.
- Withdraws the regulations published by the IFR <u>"COVID-19 Health Care Staff</u> <u>Vaccination"</u> on November 5, 2021.
- Finalizes certain provisions published in the IFR <u>"COVID-19 Vaccine Educate and</u> <u>Offer"</u> on May 13, 2021.







CMS COVID-19 Vaccine Regulatory Changes

- CMS is withdrawing all requirements to vaccinate staff for COVID-19 issued in the <u>staff vaccination</u> IFC.
- This means that the requirement to have all staff vaccinated for COVID-19 or receive a medical exemption will be removed.
 - Note: COVID-19 vaccination of health care staff and residents will be reported through the SNF Quality Reporting Program (QRP).
- CMS is finalizing the requirement from the "COVID-19 Vaccine Educate and Offer rule" which
 maintains requirements for LTC facilities to educate staff and residents about, and offer, the COVID-19
 vaccine.
 - Guidance on this rule is available in <u>QSO-21-19-NH</u>.
 - All elements of this rule are being finalized except for the language referring to LTC facility staff refusing the COVID-19 vaccine originally set forth at § 483.80(d)(3)(v).
 - Note that this rule maintains the requirement to report COVID-19 vaccine status for residents and staff to NHSN.



CMS COVID-19 Testing Changes

- CMS is removing all testing requirements issued in the interim final rule (IFR) <u>"LTC Facility Testing"</u> on September 2, 2020.
- CMS still expects facilities to conduct COVID-19 testing in accordance with accepted national standards, such as CDC recommendations.
 - Noncompliance with this expectation will be cited at F-880 for failure to implement an effective Infection Prevention and Control Program in accordance with accepted national standards.



CMS Guidance Updates

DEPARTMENT OF HEALTH & HUMAN SERVICES Centers for Medicare & Medicaid Services 7500 Security Boulevard, Mail Stop C2-21-16 Baltimore, Maryland 21244-1850



Center for Clinical Standards and Quality/Quality, Safety & Oversight Group

Ref: QSO-23-16-Hospitals

DATE: June 6, 2023

TO: State Survey Agency Directors

FROM: Director, Quality, Safety & Oversight Group (QSOG)

SUBJECT: Requirements for Hospital Discharges to Post-Acute Care Providers

Memorandum Summary

CMS is committed to ensuring that the health and safety of patients are protected when discharges from hospitals and transfers to post-acute care providers occur. Therefore, we are providing the following information:

- Reminding state agencies (SAs), accrediting organizations (AOs), and hospitals of the regulatory requirements for discharges and transfers to post-acute care providers.
- Highlighting the risks to patients' health and safety that can occur due to an unsafe discharge.
- Recommendations that hospitals can leverage to improve their discharge policies and procedures to improve and protect patients' health and safety.

- CMS identified a concern regarding resident information post-acute care providers receives from hospitals:
- Information regarding substance use disorders and mental health diagnoses or histories.
- A complete list of medications for discharge.
- Information about skin conditions, including skin tears, pressure injuries, healthcareassociated infections, cultures, treatments, etc.
- Information regarding durable medical equipment.
- Information regarding the patient's preferences for care, including end-of-life decisions.
- Communications about the patient's needs at home.



		Infect	nter-Fa tion Co	ontrol	Is the person* currently in Trans Type of Precautions (check all th Reason for Precautions: Is the person* currently on antib	at apply) 🗌 Contac
Best practice recommendation: Complete Attach copies		cepting facility. If sent with in		when transfer occurs.	List any antibiotics, current or in Antibiotic, Dose, Route, Frequ	
Constitution to the constitution						
Sending Healthcare Facility: Patient/Resident Last Name	First Name	Date of Birth	Medical De	cord Number		
Padeng Resident East Hame	ttent/resident Last Name First Name					
Name/Address of Sending Facility		Sending Unit	Sending Facility	y Phone	Has the person* received treatm (monoclonal antibody treatmen Dose, Route, Freq	t, convalescent pla
Sending Facility Contacts	Contact Name	Phone	Email			
Transferring RN/Unit						
Transferring Physician						
Case Manager / Admin / SW						5
Infection Preventionist					Vaccine	Date Adr (If kr
			Antonion Inc.	Andread of the	Influenza (seasonal)	
Does the person* currently have an infectio multidrug-resistant organism (MDRO) or ot			Colonization or History	Active Infection on Treatment	Pneumococcal (PPSV23)	
Methicillin-resistant Staphylococcus aureus	(MDSA)		(Check if YES)	(Check if YES)	Pneumococcal (PCV13)	
metriciiii resistant stapriyococcus aureus	(MRSA)					REQ
Vancomycin-resistant Enterococcus (VRE)						Dose 1:
Clostridioides difficile				COVID-19	Dose 2:	
Acinetobacter, multidrug-resistant					Booster Dose/	
Enterobacteriaceae (e.g., E. coli, Klebsiella, I Lactamase (ESBL)	ctended Spectrum Beta-				Additional Dos	
Carbapenem-resistant Enterobacteriaceae				Other:	_	
Pseudomonas aeruginosa, multidrug-resist				*Refers to patient or resident, depend	ing on transferring fo	
Candida auris						_
Other, specify (e.g., lice, scables, norovirus, i	nfluenza, COVID-19):					
If COVID-19, please include date of diagnosis	s:				Name of staff completing form (prin	it):
Does the person* currently have any of	the following? Ch	eck here 🗆 if none apply			Signature:	
Cough or requires suctioning		☐ Central line/PICC (A	Approx. date insert	ed)		
□ Diarrhea	☐ Hemodialysis cathe			If information communicated prior to	transfer:	
□Vomiting		Urinary catheter (A	pprox. date inserte	d)	Name of individual at receiving facili	ty:

Reason for Precautions:									
s the person* currently on anti	ibiotics?	□ No □	Yes						
List any antibiotics, current or in	n the prev	ious 6 mont	hs, the pers	on* has	been prescri	bed.			
Antibiotic, Dose, Route, Frequency		Treatment for		S	Start Date		oated Oate	Date/Time of Last Dose	
Has the person* received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person received treatments and the person received treatments are the person	nt, convai			Yes	Anticipated	Stop Date	Date/Tir	ne of Last Dose	
Dose, Route, Free	quericy		Start D	are	Anticipated	Dtop Date	Date/ III	ne or cast Dose	
Vaccine		Date Administered (If known)			Lot and Brand (If known)			e person* self- eiving vaccine	
Influenza (seasonal)				-			☐ Ye		
Pneumococcal (PPSV23)	-						☐ Ye		
Pneumococcal (PCV13)	_	REQUIRED		+	REQUIRED		☐ Ye	s 🗌 No	
	Dos	Dose 1:			☐ Pfizer-BioNTech				
COVID-19	Dos	Dose 2:			□ Moderna			s 🗆 No	
		Booster Dose/ Additional Dose:			☐ Other:				
Other:							☐ Ye:	s 🗆 No	
Refers to patient or resident, depen	ding on tra	ınsferring facil	ity						
Name of staff completing form (pr	int):								
Signature:						Date:			



CDC COVID-19 Infection Prevention and Control Guidance Updates

Interim IPC Recommendations for Healthcare Personnel

<u>Interim Guidance for Managing Healthcare Personnel with Infection or Exposure</u>

<u>Strategies to Mitigate Healthcare Personnel Staffing Shortages</u>



Alliant Health Solutions Resources







Questions?





GADPH Healthcare-Associated Infections (HAI) Team

State Region/Districts	Contact Information
North (Rome, Dalton, Gainesville, Athens) Districts 1-1, 1-2, 2, 10	<u>Sue.bunnell@dph.ga.gov</u> (404-967-0582)
Atlanta Metro (Cobb-Douglas, Fulton, Clayton, Lawrenceville, DeKalb, LaGrange) Districts 3-1, 3-2, 3-3, 3-4, 3-5, 4	<u>Teresa.Fox@dph.ga.gov</u> (256-293-9994) <u>Renee.Miller@dph.ga.gov</u> (678-357-4797)
Central (Dublin, Macon, Augusta, & Columbus) Districts 5-1, 5-2, 6, 7	Theresa.Metro-Lewis@dph.ga.gov (404-967-0589) Karen.Williams13@dph.ga.gov (404-596-1732)
Southwest (Albany, Valdosta) Districts 8-1, 8-2	<u>Connie.Stanfill1@dph.ga.gov (404-596-1940)</u>
Southeast (Savannah, Waycross) Districts 9-1, 9-2	<u>Lynn.Reynolds@dph.ga.gov</u> (804-514-8756)
Backup/Nights/Weekends	Joanna.Wagner@dph.ga.gov (404-430-6316)



Thank You for Your Time! Contact the AHS Patient Safety Team Patientsafety@allianthealth.org



Amy Ward, MS, BSN, RN, CIC Patient Safety Manager Amy.Ward@AlliantHealth.org 678.527.3653



Paula St. Hill, MPH, A-IPC Technical Advisor, Infection Prevention Paula.StHill@AlliantHealth.org 678.527.3619



Donald Chitanda, MPH, CIC Technical Advisor, Infection Prevention <u>Donald.Chitanda@AlliantHealth.org</u> 678.527.3651



Erica Umeakunne, MSN, MPH, APRN, CIC Infection Prevention Specialist Erica.Umeakunne@AlliantHealth.org



Save the Date

SNF and Medical Directors Office Hours:

July 21, 2023 | 11 a.m. ET

ALF and PCH

June 23, 2023 | 11 a.m. ET



Thanks Again...

- Georgia Department of Public Health
- University of Georgia





Making Health Care Better







